OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Ocugen Inc. (NASDAQ:OCGN) is one of the popular penny stocks on Robinhood to buy. On March 2, Ocugen, Inc. (NASDAQ:OCGN) announced the completion of patient enrollment for its Phase 3 liMeliGhT ...
The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization ...
Zacks Investment Research on MSN
Ocugen falls as gene therapy for eye disease lags in phase II study
Shares of Ocugen OCGN declined 8.6% on Tuesday after the company announced 12-month data from the phase II ArMaDa study evaluating its novel modifier gene therapy, OCU410, for treating geographic ...
Steven Pittler, Ph.D., at the University of Alabama at Birmingham has sought to find modifier genes for the hereditary eye disorder retinitis pigmentosa type 59. After onset in one’s late teens, RP59 ...
Add Yahoo as a preferred source to see more of our stories on Google. A genetic eye disorder Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, ...
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN) (Ocugen or the Company), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the ...
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the ...
Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced its participation in two significant upcoming conferences: the ARVO 2025 Annual Meeting in Salt Lake ...
Please provide your email address to receive an email when new articles are posted on . Low-dose OCU410 slowed lesion growth, preserved retinal tissue and stabilized visual function in three patients.
BIRMINGHAM, Ala. – Modifier genes add complexity to precision medicine. A modifier gene is one that has genetic variants such as single nucleotide changes that differ from the most common sequence in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results